Improving Treatment Outcomes of Patients With Waldenstrom Macroglobulinemia

STATEMENT OF NEED

Waldenstrom macroglobulinemia (WM) is a rare lymphoproliferative disorder characterized by lymphoplasmacytic bone marrow infiltration and the presence of serum monoclonal IgM. With an estimated 1,500 new cases reported in the United States annually, the malignancy accounts for 2% of non-Hodgkin lymphomas. Unfortunately, WM is considered incurable with available therapies. Patients with low- and intermediate-risk disease have 5-year survival rates of 87% and 68%, respectively, whereas those with high-risk disease have a 5-year survival rate of only 36%.

TARGET AUDIENCE

Hematology/oncology physicians, oncology advanced practitioners, oncology nurses, and other health care professionals involved in the treatment of patients with WM

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

1. Assess factors to risk stratify patients with WM
2. Differentiate emerging efficacy and safety data on novel therapeutic approaches for treatment-naive and relapsed/refractory WM
3. Apply strategies to monitor and manage adverse events associated with novel therapies for WM

Note: The learning objectives listed above apply to nurse practitioners and registered nurses in addition to physicians.